keyword
MENU ▼
Read by QxMD icon Read
search

Bridge to transplant

keyword
https://www.readbyqxmd.com/read/29235399/reviewing-the-use-of-ventricular-assist-devices-in-the-elderly-where-do-we-stand-today
#1
Nandini Nair, Enrique Gongora
Implantation of left ventricular assist devices (LVADS) in older patients appears to be an attractive option in the wake of donor shortage and increasing incidence and prevalence of end stage heart failure. Since the inception of the artificial heart program half a century ago tremendous progress in research and development has led to utilization of more sophisticated devices. VADs have therefore emerged as a successful therapy for extending life with meaningful quality. Areas covered: This review will address the use of LVADS as a bridge to transplantation, destination therapy and comparison of LVAD therapy with alternate list heart transplantation in the elderly population...
December 13, 2017: Expert Review of Cardiovascular Therapy
https://www.readbyqxmd.com/read/29234595/ibrutinib-as-a-bridge-to-transplant-in-high-risk-chronic-lymphocytic-leukemia-a-case-report-and-review-of-the-literature
#2
Arcari Annalisa, Bassi Simona, Pochintesta Lara, Trabacchi Elena, Moroni Carlo Filippo, Rossi Angela, Zanlari Luca, Vallisa Daniele
The treatment landscape of chronic lymphocytic leukemia (CLL) has been challenged by the advent of novel classes of drugs, such as B-cell receptor (BCR)-inhibitors and BCL-2 antagonists. In selected high-risk patients, the choice to start allogeneic hematopoietic stem cell transplantation (alloHCT) or continue these agents is a matter of debate. Furthermore, published data about the impact on the feasibility of alloHCT and the optimal timing of administration are limited. Here we present a case of relapsed TP53 mutated CLL treated with ibrutinib as a bridge to alloHCT, discussing risks and benefits of different treatment options in a "real life" situation...
2017: Leukemia Research Reports
https://www.readbyqxmd.com/read/29234013/the-differentiation-stage-of-transplanted-stem-cells-modulates-nerve-regeneration
#3
Ching-Wen Huang, Wen-Chin Huang, Xuefeng Qiu, Flavia Fernandes Ferreira da Silva, Aijun Wang, Shyam Patel, Leon J Nesti, Mu-Ming Poo, Song Li
In regenerative medicine applications, the differentiation stage of implanted stem cells must be optimized to control cell fate and enhance therapeutic efficacy. We investigated the therapeutic potential of human induced pluripotent stem cell (iPSC)-derived cells at two differentiation stages on peripheral nerve regeneration. Neural crest stem cells (NCSCs) and Schwann cells (NCSC-SCs) derived from iPSCs were used to construct a tissue-engineered nerve conduit that was applied to bridge injured nerves in a rat sciatic nerve transection model...
December 12, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29233199/hypoplastic-left-heart-in-turner-s-syndrome-a-primary-indication-for-transplant
#4
Joseph Philip, Dipankar Gupta, Mark S Bleiweis, Biagio A Pietra, Himesh V Vyas
Survival for hypoplastic left heart syndrome patients following the Norwood procedure is 71-90%. Mortality in patients with Turner's syndrome and hypoplastic left heart syndrome after conventional palliation (Norwood operation) has been reported as high as 80%. This questions the approach of traditional staged palliation. Here, we report a patient with hypoplastic left heart syndrome and Turner's syndrome bridged to orthotopic heart transplantation following a hybrid procedure.
December 13, 2017: Cardiology in the Young
https://www.readbyqxmd.com/read/29230127/intraarterial-liver-directed-therapies-the-role-of-interventional-oncology
#5
REVIEW
Jenson Ma, Juan Martin Gimenez, Tyler Sandow, Daniel Devun, David Kirsch, Paul Gulotta, Patrick Gilbert, Dennis Kay
Background: Since the early 1990s, the minimally invasive image-guided therapies used in interventional oncology to treat hepatocellular carcinoma have continued to evolve. Additionally, the range of applications has been expanded to the treatment of hepatic metastases from colorectal cancer, neuroendocrine tumors, cholangiocarcinoma, breast cancer, melanoma, and sarcoma. Methods: We searched the literature to identify publications from 1990 to the present on various image-guided intraarterial therapies and their efficacy, as well as their role in the management of primary and secondary liver malignancies...
2017: Ochsner Journal
https://www.readbyqxmd.com/read/29223289/frequency-and-consequences-of-right-sided-heart-failure-after-continuous-flow-left-ventricular-assist-device-implantation
#6
Chitaru Kurihara, Andre C Critsinelis, Masashi Kawabori, Tadahisa Sugiura, Gabriel Loor, Andrew B Civitello, Jeffrey A Morgan
Postoperative right-sided heart failure (RHF) is a common complication after continuous-flow left ventricular assist device implantation. Studies have examined RHF in the perioperative period, but few have assessed late-onset RHF. We analyzed the incidence of early and late RHF in patients with HeartMate II and HeartWare left ventricular assist devices and associated morbidity, mortality, and independent predictors of RHF. We retrospectively analyzed records of 526 patients with chronic heart failure who underwent continuous-flow left ventricular assist device implantation; 147 (27...
October 31, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/29221923/combination-of-neoadjuvant-transcatheter-arterial-chemoembolization-and-orthotopic-liver-transplantation-for-the-treatment-of-cirrhotomimetic-hepatocellular-carcinoma
#7
Peiman Habibollahi, Sara P Shamchi, Rashmi Tondon, Brett L Ecker, Terence P Gade, Stephen Hunt, Michael C Soulen, Emma E Furth, Matthew H Levine, Gregory Nadolski
PURPOSE: To examine differences in outcome and response of cirrhotomimetic (CMM) hepatocellular carcinoma (HCC) to a combination of bridging transcatheter arterial chemoembolization and orthotopic liver transplantation (OLT) compared with non-CMM HCC. MATERIALS AND METHODS: All patients with pathologically proven CMM HCC who underwent bridging transcatheter arterial chemoembolization before OLT between 2007 and 2013 (n = 23) were retrospectively compared with a control group of patients with pathologically proven non-CMM HCC (n = 46)...
December 5, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29221351/extracorporeal-membrane-oxygenation-system-as-a-bridge-to-reparative-surgery-in-ventricular-septal-defect-complicating-acute-inferoposterior-myocardial-infarction
#8
Jose Rozado, Isaac Pascual, Pablo Avanzas, Daniel Hernandez-Vaquero, Ruben Alvarez, Rocio Díaz, Beatriz Díaz, María Martín, Amelia Carro, Guillermo Muñiz, Jacobo Silva, Cesar Moris
Post-infarction ventricular septal defect (VSD) is a rare but potentially lethal complication of acute myocardial infarction. Medical management is usually futile, so definitive surgery remains the treatment of choice but the risk surgery is very high and the optimal timing for surgery is still under debate. A 55-year-old man with no previous medical history attended the emergency-room for 12 h evolution of oppressive chest pain and strong anginal pain 7 days ago. On physical examination, blood pressure was 96/70 mmHg, pansystolic murmur over left sternal border without pulmonary crackles...
September 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29221320/bridging-to-lung-transplantation-with-extracorporeal-circulatory-support-when-or-when-not
#9
REVIEW
Gabriel Loor, Leo Simpson, Amit Parulekar
Patients with end-stage lung disease who are candidates for lung transplantation may acutely decompensate before a donor organ becomes available. In this scenario, extracorporeal life support (ECLS) may be considered as a bridge to transplant or as a bridge to decision. In the current chapter, we review the indications, techniques, and outcomes for bridging to lung transplantation with ECLS.
September 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29217463/electrical-storm-in-the-early-phase-of-heartmate%C3%A2-ii-device-implantation-incidence-risk-factors-and-prognosis
#10
Jerome Corre, François Picard, Rodrigue Garcia, Adlane Zemmoura, Nicolas Derval, Arnaud Denis, Antoine Romen, Karine Nubret, Pierre Jais, Michel Haissaguerre, Pierre Dos Santos, Laurent Barandon, Frederic Sacher
BACKGROUND: Ventricular arrhythmia is common after left ventricular assist device (LVAD) implantation, especially in the early postoperative phase (<30 days). AIM: To identify the incidence of and risk factors for electrical storm (ES) occurring within 30 days of HeartMate® II implantation. METHODS: We reviewed data from all consecutive patients undergoing HeartMate® II device implantation at our institution from January 2008 to December 2014...
December 4, 2017: Archives of Cardiovascular Diseases
https://www.readbyqxmd.com/read/29217220/transaxillary-implantation-of-the-impella-cp-mechanical-circulatory-support-device-as-a-bridge-to-heart-transplant-first-experience-in-spain
#11
David Couto-Mallón, Francisco Estévez-Cid, Miguel Solla-Buceta, Carlos García-Velasco, María G Crespo-Leiro, José Joaquín Cuenca-Castillo
No abstract text is available yet for this article.
December 4, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/29211918/decellularized-human-placenta-supports-hepatic-tissue-and-allows-rescue-in-acute-liver-failure
#12
Zurab Kakabadze, Anne Kakabadze, David Chakhunashvili, Lika Karalashvili, Ekaterine Berishvili, Yogeshwar Sharma, Sanjeev Gupta
Tissue engineering with scaffolds to form transplantable organs is of wide interest. Decellularized tissues have been tested for this purpose, although supplies of healthy donor tissues, vascular recellularization for perfusion and tissue homeostasis in engineered organs pose challenges. We hypothesized decellularized human placenta will be suitable for tissue engineering. The universal availability and unique structures of placenta for accommodating tissue, including presence of embedded vessels, were major attractions...
December 6, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29211308/dose-schedule-safety-and-efficacy-of-guadecitabine-in-relapsed-or-refractory-acute-myeloid-leukemia
#13
Gail J Roboz, Hagop M Kantarjian, Karen W L Yee, Patricia L Kropf, Casey L O'Connell, Elizabeth A Griffiths, Wendy Stock, Naval G Daver, Elias Jabbour, Ellen K Ritchie, Katherine J Walsh, David Rizzieri, Scott D Lunin, Tania Curio, Woonbok Chung, Yong Hao, James N Lowder, Mohammad Azab, Jean-Pierre J Issa
BACKGROUND: Outcomes for patients with relapsed or refractory acute myeloid leukemia (AML) are poor. Guadecitabine, a next-generation hypomethylating agent, could be useful in treating such patients. METHODS: In this multicenter, open-label, phase 2 dose-expansion study, AML patients from 10 North American medical centers were first randomized (1:1) to receive subcutaneous guadecitabine at 60 or 90 mg/m2 on 5 consecutive days in each 28-day cycle (5-day regimen)...
December 6, 2017: Cancer
https://www.readbyqxmd.com/read/29207679/italian-real-life-experience-with-brentuximab-vedotin-results-of-a-large-observational-study-on-234-relapsed-refractory-hodgkin-s-lymphoma
#14
Cinzia Pellegrini, Alessandro Broccoli, Alessandro Pulsoni, Luigi Rigacci, Caterina Patti, Guido Gini, Donato Mannina, Monica Tani, Chiara Rusconi, Alessandra Romano, Anna Vanazzi, Barbara Botto, Armando Santoro, Stefan Hoaus, Gian Matteo Rigolin, Pellegrino Musto, Patrizio Mazza, Stefano Molica, Paolo Corradini, Angelo Fama, Francesco Gaudio, Michele Merli, Fioravante Ronconi, Giuseppe Gritti, Daniele Vallisa, Patrizia Tosi, Anna Marina Liberati, Antonello Pinto, Vincenzo Pavone, Filippo Gherlinzoni, Maria Paola Bianchi, Stefano Volpetti, Livio Trentin, Maria Cecilia Goldaniga, Maurizio Bonfichi, Amalia De Renzo, Corrado Schiavotto, Michele Spina, Angelo Michele Carella, Vittorio Stefoni, Lisa Argnani, Pier Luigi Zinzani
A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48...
October 31, 2017: Oncotarget
https://www.readbyqxmd.com/read/29206595/assessment-of-response-to-transcatheter-arterial-chemoembolization-with-doxorubicin-eluting-microspheres-tumor-biology-and-hepatocellular-carcinoma-recurrence-in-a-5-year-transplant-cohort
#15
Tyler A Sandow, Stephen E Arndt, Abeer A Albar, Daniel A DeVun, David S Kirsch, Juan M Gimenez, Humberto E Bohorquez, Patrick J Gilbert, Paul T Thevenot, Kelley G Nunez, Gretchen A Galliano, Ari J Cohen, Dennis Kay, Paul M Gulotta
Purpose To assess response to transcatheter arterial chemoembolization (TACE) based on immune markers and tumor biology in patients with hepatocellular carcinoma (HCC) who were bridged to liver transplantation, and to produce an optimized pretransplantation model for posttransplantation recurrence risk. Materials and Methods In this institutional review board-approved HIPAA-compliant retrospective analysis, 93 consecutive patients (73 male, 20 female; mean age, 59.6 years; age range, 23-72 years) underwent TACE with doxorubicin-eluting microspheres (DEB) (hereafter, DEB-TACE) and subsequently underwent transplantation over a 5-year period from July 7, 2011, to May 16, 2016...
December 4, 2017: Radiology
https://www.readbyqxmd.com/read/29203213/examining-the-role-of-extracorporeal-membrane-oxygenation-in-patients-following-suspected-or-confirmed-suicide-attempts-a-case-series
#16
Adeel Abbasi, Cynthia Devers, Christopher S Muratore, Colin Harrington, Corey E Ventetuolo
The decision to offer extracorporeal membrane oxygenation (ECMO) is based on a risk/benefit assessment and the likelihood of a treatable underlying condition or the feasibility of destination therapy (durable mechanical support or thoracic organ transplantation) should heart-lung function fail to improve. Patients who present following suspected suicide attempts who fail medical therapy may pose a dilemma for clinicians. An assessment to determine if a patient has a high likelihood of psychiatric recovery such that bridging with ECMO or ultimately destination therapy could or should be offered is not always feasible in the setting of critical illness...
October 18, 2017: Journal of Critical Care
https://www.readbyqxmd.com/read/29198806/toronto-bridges-to-successful-lung-transplantation
#17
EDITORIAL
Dirk Van Raemdonck, Arne Neyrinck, Robin Vos, Geert M Verleden
No abstract text is available yet for this article.
November 7, 2017: Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/29198789/yesterday-s-heroic-measure-is-now-standard-procedure-extracorporeal-membrane-oxygenation-as-a-bridge-to-lung-transplant
#18
EDITORIAL
Victor van Berkel
No abstract text is available yet for this article.
November 7, 2017: Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/29198224/case-report-and-review-of-the-literature-the-utilisation-of-a-ventricular-assist-device-as-bridge-to-recovery-for-anthracycline-induced-ventricular-dysfunction
#19
Diane Krasnopero, Alfred Asante-Korang, Jeffrey Jacobs, Stacie Stapleton, Jennifer Carapellucci, Mathew Dotson, Gary Stapleton
Ventricular assist devices are used in children with heart failure as a bridge to myocardial recovery or cardiac transplantation. Anthracyclines cause cardiac toxicity and may result in acute or long-term cardiac failure. We describe the use of a ventricular assist device as a bridge to recovery in a child with severe acute anthracycline-induced cardiomyopathy, and we review the associated literature. A 6-year-old girl was treated for acute myeloblastic leukaemia with daunorubicin and mitoxantrone. After 2 weeks her final dose of chemotherapy, her Left Ventricular Ejection Fraction decreased to 21%...
December 4, 2017: Cardiology in the Young
https://www.readbyqxmd.com/read/29194964/personal-viewpoint-the-bridge-between-transplantation-and-regenerative-medicine-beginning-a-new-banff-classification-of-tissue-engineering-pathology
#20
K Solez, K C Fung, K A Saliba, V L C Sheldon, A Petrosyan, L Perin, J F Burdick, W H Fissell, A J Demetris, L D Cornell
The science of regenerative medicine is arguably older than transplantation - the first major textbook was published in 1901 - and a major regenerative medicine meeting took place in 1988, three years before the first Banff transplant pathology meeting. However, the subject of regenerative medicine/tissue engineering pathology has never received focused attention. Defining and classifying tissue engineering pathology is long overdue. In the next decades, the field of transplantation will enlarge at least tenfold, through a hybrid of tissue engineering combined with existing approaches to lessening the organ shortage...
December 1, 2017: American Journal of Transplantation
keyword
keyword
31544
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"